Breaking Down Practices v1.0: Applications

1
Breaking Down Practices v1.0 Applications

• Megan Palmer
• May 10th 2011

2
PCSBI FAQs
3
What are new, real challenges that SB poses in
this domain?

• Justifying / distinguishing syn bio vs trad
  genetic eng approaches
• Abstraction, standardization, composability
  enabling complex systems engineering
• Difference in process vs kind (e.g. fast, cheap,
  safe vs altogether different)
• Taking advantage of biologys toolkit
  (reproduction, evolution, interaction)
• Success often evaluated largely by applications,
  whereas greatest benefit may be cross-cutting
  technology platforms (i.e. tools)
• e.g. (SynB)ERC top-down model in which testbeds
  drive technology
• Merits of high vs low risk / benefit technologies
  (Lim e.g. toys)?
• Articulating present reality, future promises and
  intermediate successes

4
How might this relate to your current or future
work?

• (Re-)inventing the wheel (were different yet the
  same)
• Fragmented regulatory landscape largely
  application-dependent

5
What case studies might be relevant?

• SynBERCs testbed portfolio - rationale (or lack
  thereof) as motivating for technology platform
  development
• Retired Testbeds TDB
• Current Testbeds MCF, Industrial
• Future Testbeds Cyanobacteria, Stem Cells
• Syn bio-labeled commercial applications
• e.g. biofuels. artemisinin

6
Who are people that might help us work through
these problems?

• Jay Keasling - SynBERCs model
• Adam Arkin - Recent white paper on the new
  bioeconomy
• Harvey Blanch (CSTO _at_ JBEI) - BioEconomics
• Tom Kalil _at_ OSTP - Roadmap for Fed Investment in
  Biotech

7
Can you find articles (or other resources) we
might draw upon for background?

• Innumerable Reviews Touching on Application
  Landscapes and Roadmaps
• Synthetic Society Meeting Notes
• Arkin White Paper on The New Bioeconomy

8
(No Transcript)
9
Akin A. 2008.Setting the standard in synthetic
biology. Nature Biotechnology.

• Such community repositories will yield the most
  benefit when synthetic-biology designs scale to
  systems requiring many interacting parts, thereby
  limiting the utility of even inspired tinkering
  to optimize function.Although we cannot quite
  yet imagine what synthetic biological
  applications might require the numbers and
  quality of elements on which these advanced
  technological systems rely, it is economically
  and socially important that we improve the
  efficiency, reliability and predictability of our
  biological designs.

10
Notes fr. Discussions with Adam Arkin
penicillin
Programs
syn bio
route?
metabolic eng
Pipes
rational protein eng
Discovery
Design